The Knight ADRC has supported many investigators at Washington University and at other institutions over the years. We wish to avoid the situation where two investigators study the same research question to avoid duplication of effort and potential conflict. To determine if your topic has already been studied with our resources, please search our database. If you find that your topic or a related topic has been submitted, you may wish to contact the investigator to inquire about their findings to determine how you might proceed. You may wish to collaborate or modify your request to avoid overlap. The results below reflect requests made since online requests have been accepted. As such, not all fields will have data as certain information, such as aims, were not collected until recently. If an entry has been assigned an ID number (e.g. T1004), the full request has been submitted and is either approved, disapproved or in process. If an entry has no ID number, then it represents a submission that has not yet been reviewed. Search terms are applied across an entire requests application including variables not displayed below. A more specific, detailed search may yield better results depending upon your needs.
Search Terms:
Investigator: Eran Hornstein
Project Title: miRNAs as diagnostic biomarkers for Alzheimer’s disease
Date: December 21, 2021 at 5:02 pm
Request ID: T2001
Aim 1: Testing a microRNA classifier for FTD on an AD plasma cohort
Aim 2: Establishing plasma microRNAs as markers for differential diagnosis between AD and FTD
Aim 3: Developing a machine learning algorithm for AD classification based on plasma microRNAs
Aim 4:
Investigator: Richard I. Morimoto
Project Title: Drug Discovery to Ameliorate Proteostasis Failure in Tauopathies
Date: December 21, 2021 at 5:02 pm
Request ID: T2002
Aim 1: To develop and validate a panel of proteostasis sensors and reporters for all arms of the Proteostasis Network (PN) that robustly and quantitatively reports on each branch of the PN in the context of mutant Tau and the effects of aging.
Aim 2: To test the hypothesis that the age-dependent deficiencies in PN capacity in animal and cell models of Tauopathy can be reset by pharmacologic regulation of the PN employing using small molecule proteostasis regulators (PRs).
Aim 3:
Aim 4:
Investigator: J�r�me Braudeau, PhD
Project Title: Optimization of a blood diagnosis of the silent phase of Alzheimer’s disease
Date: December 21, 2021 at 5:02 pm
Request ID: T2003
Aim 1: Improve our algorithm by learning on new plasma samples from different genetic origin and environmental background
Aim 2: Confirm the performance of the test on North American blood samples
Aim 3:
Aim 4:
Investigator: Mary Jo LaDu
Project Title: Oligomeric Ab Levels in Human Plasma as a Mechanistic Biomarker for Alzheimer’s Disease
Date: December 21, 2021 at 5:02 pm
Request ID: T2004
Aim 1: Develop a biomarker based on oAb in plasma for early detection of AD and as an endpoint in the therapeutic development of AD treatment.
Aim 2:
Aim 3:
Aim 4:
Investigator: Rawan Tarawneh, MD
Project Title: CSF and Plasma Eotaxins As Diagnostic Biomarkers of Alzheimer Disease
Date: December 21, 2021 at 5:02 pm
Request ID: T2005
Aim 1: Examine the diagnostic value of CSF and plasma eotaxin-1 and eotaxin-3 in differentiating AD from controls
Aim 2: Investigate correlations of CSF and plasma eotaxins with CSF markers of amyloid and tau pathology (tau, p-tau181, Ab42) and markers of neuronal/synaptic injury (Ng and VILIP-1)
Aim 3: Examine associations of CSF and plasma eotaxins with cross-sectional and longitudinal cognitive assessments (including episodic memory, semantic memory, working memory, visuospatial, and global composite scores) and CDR-SB
Aim 4: Examine correlations of CSF and plasma eotaxins with whole brain and regional atrophy (cross-sectional only)
Investigator: Beau Ances
Project Title: Gut Dysbiosis and Intestional Dysfunction in AD
Date: December 21, 2021 at 5:02 pm
Request ID: T2006
Aim 1: Characterize gut bacterial content and organ permeability in adults in different stages of AD
Aim 2: Identify changes in bacterial content and organ permeability in individuals who advance to preclinical AD or clinical AD.
Aim 3: Compare bacterial content and organ permeability to AD biomarkers obtained from other projects.
Aim 4:
Investigator: Laura Ibanez
Project Title: Plasma cell-free RNA as non-invasive Biomarker for Neurodegeneration
Date: December 21, 2021 at 5:02 pm
Request ID: T2007
Aim 1: Develop a predictive model for Alzheimer Disease using RNA species free in Plasma
Aim 2: Replicate the predictive model in an independent sample of presymptomatic individuals
Aim 3: Test if the predictive model is agnostic to ethnic background
Aim 4:
Investigator: Russell Swerdlow
Project Title: CSF biomarker characterization in aging and AD
Date: December 21, 2021 at 5:02 pm
Request ID: T2008
Aim 1: Aim 1. Show feasibility to measure cerebrospinal fluid (CSF) A/T/N biomarkers in cognitively healthy older adults and individuals with AD.
Aim 2:
Aim 3:
Aim 4:
Investigator: Harari, Cruchaga and Karch
Project Title: A molecular and cellular atlas of Alzheimer�s Disease and Neuropath-free brains
Date: December 21, 2021 at 5:02 pm
Request ID: T2009
Aim 1: To identify glial- and neuronal-specific events that lead to AD by generating single-nuclei data for AD and neuropath-free brains
Aim 2: To perform cell-type specific differential expression analyses
Aim 3: To identify the cell-type gene co-expression and co-regulated networks disrupted by AD
Aim 4: To identify cell-type expression quantitative traits locus (Ct-eQTL) by integrating single-nuclei data with GWAS and whole genome/exome sequencing
Investigator: Marco Colonna
Project Title: MENINGEAL B CELLS IN AGING AND ALZHEIMER�S DISEASE
Date: December 21, 2021 at 5:02 pm
Request ID: T2010
Aim 1: TEST THE HYPOTHESIS THAT MENINGEAL B CELLS ORIGINATE FROM THE CALVARIAL BONE MARROW.
Aim 2: TO TEST THE HYPOTHESIS THAT THE DURA MENINGES B CELLS CLONALLY EXPAND DURING AGING AND BECOME AUTOREACTIVE ABC.
Aim 3: PROFILING THE MOLECULAR LANDSCAPE OF HUMAN DURA BY SINGLE-NUCLEI RNASEQ.
Aim 4: